Pliant Therapeutics
PLRX
77 hedge funds and large institutions have $513M invested in Pliant Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 11 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
1% less ownership
Funds ownership: 85.53% → 84.53% (-1%)
5% less funds holding
Funds holding: 81 → 77 (-4)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
43% less capital invested
Capital invested by funds: $894M → $513M (-$381M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $812K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.12M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.76M |
| 3 |
Morgan Stanley
New York
|
+$2.49M |
| 4 |
CA
CHI Advisors
New York
|
+$2.48M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.13M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.13M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.55M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.49M |
PLRX Hedge Fund Activity: Q3 2021 in Review
77 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2021, worth a combined $513M — down 43% from $894M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PLRX and 7 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 30 added.
The largest buyer was Vanguard Group, adding an estimated $3.12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $14.3M sold.
- 77 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2021, down from 81 in Q2 2021.
- Funds reported $513M of Pliant Therapeutics stock for Q3 2021, down 43% quarter-over-quarter.
- 7 funds opened new Pliant Therapeutics positions in Q3 2021 and 11 closed out, a net change of -4 holders.
- The largest Pliant Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $3.12M added.
- The largest Pliant Therapeutics seller in Q3 2021 was Farallon Capital Management, an estimated $14.3M sold.
Based on aggregated 13F filings for Q3 2021.